Irena Barsky

CONTACT

Ori Lubin

CONTACT

Lead Sponsor

P-Cure

Collaborators

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

No

•Pathologically (histologically or cytologically) proven malignancy
•Treatment planning analysis shows advantage to proton over photon treatments
•both malignancies (such as thoracic tumors) as well as metastatic lesions (such as metastatic breast cancer or colorectal cancer to the lungs) are allowed
•Patient must have CT confirmation of the tumor
•Patients must have a life expectancy of \> 6 months
•Patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least 10 mm on CT imaging).
•Patients must be a candidate for definitive radiation dose
•There are no limits on prior therapy. Patients are allowed to have prior chemotherapy and surgery. Patients are allowed to have concurrent chemotherapy with radiation treatment. Patients are allowed to have chemotherapy or surgery after radiation treatment

•1. Severe, active co-morbidity, defined as follows:
•1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
•2. Transmural myocardial infarction within the last 6 months
•3. Chronic obstructive pulmonary disease exacerbation or other respiratory illness other than the diagnosed lung cancer requiring hospitalization or precluding study therapy within 30 days before registration
•4. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition (protocol may be significantly immunosuppressive endangering AIDS patients)
•2. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
•3. Patients with life expectancy \< 6 months
•4. Patients that participate in another, active clinical trial carried out concurrently with this protocol